A Versatile Tool to Study Immune Checkpoint Therapeutics: Syngeneic Tumor Mouse Models in vivo

Transcription

1 The Solution Provider for Drug Discovery in Oncology A Versatile Tool to Study Immune Checkpoint Therapeutics: Syngeneic Tumor Mouse Models in vivo Holger Weber - 1 -

2 Drug discovery platform for oncology at ProQinase Recombinant Protein Production Biochemical Kinase Assay Services Cellular Assay Services In Vivo Testing Services - 2 -

3 In vivo testing today/ past A C B D Human xenografts B role of immune system neglected - 3 -

4 In vivo testing Human xenografts B future/ now A C B D Syngeneic models C testing of immunmodulatory activity obligatory - 4 -

5 Syngeneic models revival of old tumor models matched cytokine network labeled cell lines functional immune system orthotopic tumor tissue = host cells metastasis reduced cost reliable rapid - 5 -

6 ProQinase s syngeneic tumor model platform Cell line Entity Validated syngeneic models subcutaneous orthotopic metastasis 4T1 Breast B16.F1 Skin Clone M-3 Skin - - Ct26wt Colon - LL/2 Lung - - MC38-CEA Colon - - RENCA Kidney

7 Tumor infiltrating leukocytes Tumor regression CD8 + M1 CD8 + CTL Macrophage CTL CD8 + CTL M1 CD8 + Macrophage CTL Tumor promotion CD4 + CD4 tumor + cell M2 T reg CD4 + T reg MDSC Macrophage T reg MDSC MDSC MDSC MDSC M2 CD4 + Macrophage T CD4 + reg T reg M2 Macrophage MDSC - 7 -

8 Frequency of immune cell populations in syngeneic tumors Ct26wt B16. F1 4T1 RENCA - 8 -

9 Frequency of immune cell populations in syngeneic tumors M2 Macrophages M-MDSC Ct26wt CD8+ Tcell B16. F1 CD8+ Tcell PMN-MDSC MDSC M2 Macrophages MDSC M1 Macrophages 4T1 RENCA M1 Macrophages CD8+ Tcell CD8+ Tcell - 9 -

10 Testing the immune checkpoint inhibitor α PD-L1 Implantation: 4T1, B16.F1, Ct26wt, RENCA Treatment: α-pd-l1, biw Analysis: tumor growth flow cytometry Nguyen & Ohashi, Nature Reviews Immunology, 15,

11 tumor volume (mm 3 ) +/- SEM tumor volume (mm 3 ) +/- SEM tumor volume (mm 3 ) +/- SEM tumor volume (mm 3 ) +/- SEM Effect of α PD-L1 treatment on tumor growth 6 4T1 15 B16.F day after tumor implantation Ct26wt day after tumor implantation 8 RENCA day after tumor implantation day after tumor implantation Ct26wt is inhibited by treating with α-pd-l1 Group 1: vehicle Group 2: α PD-L1 antibody

12 tumor volume [mm³] Long lasting treatment effect Implantation: Ct26wt s, s.c. Treatment: α-pd-l1 antibody 2 15 Re-challenge with Ct26wt s day after tumor implantation

13 CD4 CD25 N of cells/ 1 mio. leukocytes SS SS T cell analysis in Ct26wt tumor tissue leukocytes 5 vehicle α-pd-l1 CD45 T cells CD CD4 T cells 1 CD4 T cells CD8 T cells T reg T reg CD8 FoxP3-13 -

14 SS Ly6G N of cells/ 1 mio. leukocytes SS MDSC analysis in Ct26wt tumor tissue vehicle α-pd-l1 leukocytes CD45 myeloid cells neutrophils 5 PMN- MDSCs Neutrophils M- MDSCs PMN- MDSCs M- MDSCs CD11b Ly6C

15 CD11b CD26 (MMR) tumor volume [mm³] N of cells/ 1 mio. leukocytes SS Macrophage analysis in Ct26wt tumor tissue vehicle α-pd-l1 leukocytes CD45 macrophages Ct26wt vehicle tumor ratio M2 3 2 M2 M1 ratio M2/M1 F4/8 MHC II M1 1 r 2 =, M2/M1 macrophage ratio

16 CD4 CD4 Ly6G Ly6G Summary 4T1 tumor B16.F1 tumor not inhibited by α- PD-L1 treatment high number of PMN- MDSCs PMN- MDSCs not inhibited by α- PD-L1 treatment high number of M- MDSCs M- MDSCs Ly6C Ly6C Ct26wt tumor RENCA tumor inhibited by α-pd-l1 treatment high number of Macrophages marginally affected by α-pd-l1 treatment low number of T cells high number of T cells CD8 CD8 Assistance in selecting the best model for your target

17 In Vivo Tumor Models ProQinase Thank you taken from Wikipedia In Vivo Veritas